Anti-TNF tedavi ile ilişkili lupus like sendromu

Şentürk, Elvan; Özsu, Savaş; Çapkın, Erhan; Türkyilmaz, Atilla

doi:10.5578/tt.46502

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, a higher proportion of patients treated with IFX, ADA, ETN, GOL and CZP may develop ANA>1:40, anti-dsDNA and other autoantibodies compared with placebo. In some patients, including those with positive rheumatoid factor, a lupus-like syndrome or skin reactions clinically and at pathology, compatible with subacute cutaneous lupus or discoid lupus, can occur ( 73 , 74 ). Thus, the new finding of anti-dsDNA antibodies must lead to anti-TNF drug discontinuation ( 75 ).…”

Section: Resultsmentioning

confidence: 99%

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Perricone,

Castellucci,

Cafaro

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The treatment of patients with rheumatoid arthritis (RA) has dramatically changed in the past 30 years. Currently, numerous conventional, biologic, and targeted synthetic DMARDs have been licensed and used following recommendations provided by international and national scientific societies. However, the availability of biosimilars and the increasing necessity of savings impacted on the local/national prescription of these drugs. The information provided by data sheet of every single drug is a decisive factor on the choice of a certain treatment merged with the patient’s profile. Thus, our purpose was to construct a rational algorithm for the treatment strategy in RA according to costs and the product leaflet of the biologic and targeted-synthetic DMARDs currently licensed in Italy. We used the most recent available recommendations and then we performed a review of the literature considering all the factors that are known to influence drug safety/effectiveness. All these factors were considered in the context of the data sheets of currently available originators and biosimilars.

show abstract

Section: Resultsmentioning

confidence: 99%

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Perricone,

Castellucci,

Cafaro

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Etanercept

2018

Reactions Weekly

View full text Add to dashboard Cite

Crohn tanılı hastada adalimumab ilişkili lupus benzeri sendrom

Can¹,

Demir²,

Gürler³

et al. 2020

Anadolu Güncel Tıp Dergisi

View full text Add to dashboard Cite

Crohn hastalığı tüm gastrointestinal sistemi tutan sistemik otoimmun bir hastalıktır. Sık kullanılan anti-TNF-alfa'ya bağlı olarak ilaç ilişkili lupus gibi otoimmun hastalıklar gözlenmektedir. Vakamız, azatioprin ile akut pankreatit gelişen ve sonrasında adalimumaba geçilen, adalimumab kullanımı sonrası lupus benzeri sendrom gelişen Crohn hastasıdır. Bu yan etkilerin bir kısmı otoimmunite ile ilgili olup Th2 sitokin yanıtının artışı ve sonucunda otoantikor üretimi ile ilişkilidir. İlaç ilişkili lupus, suçlu ilacın kesilmesiyle klinik bulguların geri dönebildiği bir durumdur. Anti-TNF-alfa kullanan hastalarda gelişebileceği akılda tutulmalıdır.

show abstract

Anti-TNF tedavi ile ilişkili lupus like sendromu

Abstract: SummAry lupus-like syndrome in patients treated with anti-tnf-α factorsA 56-year-old male patient presented with history of complaints of night sweats, short ness of breath, cough and yellow sputum, fever. There was a history of tumor neurosis factor-alpha (etanercept)

Cited by 3 publications

References 8 publications

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Etanercept

Crohn tanılı hastada adalimumab ilişkili lupus benzeri sendrom

Contact Info

Product

Resources

About